Taconic Biosciences is First and Only Animal Vendor to Announce All Commercial Mouse Colonies Free of New Pathogen

    NEXT STORY
    Tempus Announces (TIME) Trial Service, a New Integrated Molecular Evaluation that Leverages Artificial Intelligence to Rapidly Match Cancer Patients to Clinical Trials
    PREV STORY
    Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

    author_avatar
    NASDAQ Market News

    FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease

    Primary efficacy endpoints met in all three studies: non-dialysis, incident dialysis, and stable dialysis ...

    author_avatar
    NASDAQ Market News

    Idorsia is initiating REACT – Phase 3 registration study with clazosentan

    REACT assesses clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ...

    author_avatar
    NASDAQ Market News